<DOC>
	<DOCNO>NCT01316341</DOCNO>
	<brief_summary>pharmacokinetics , pharmacodynamics safety tolerability single multiple oral dos BI 10773 low dose daily ( q.d . ) high dose q.d . administer Chinese female male patient type 2 diabetes investigate .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics , Safety , Tolerability Empagliflozin Chinese Female Male Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Chinese male female patient proven diagnosis type 2 diabetes mellitus treat diet exercise maximum two oral antidiabetic agent except thiazolidinediones least one agent take 50 % maximum dose less , unchanged least 12 week randomization 2 . Glycosylated haemoglobin A1 ( HbA1c ) &lt; =8.5 % &gt; =7.0 % screening , age &gt; =21 age &lt; =70 year ( male female patient ) , BMI &gt; =19 &lt; =40 kg/m2 3 . Signed date write informed consent date Visit 1 accordance GCP local legislation . Exclusion criterion : 1 . Patient discontinue antidiabetic treatment insulin glitazones , DPPIV least 12 week randomization 2 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast screen visit 3 . Clinically relevant concomitant disease type 2 diabetes , hyperlipidaemia medically treat hypertension , : 4 Any late stage complication diabetes ( e.g . retinopathy , polyneuropathy , vegetative disorder , diabetic foot ) 5 Renal insufficiency ( calculated creatinine clearance &lt; 80 ml/min/1.73mÂ² ) 6 Cardiac insufficiency NYHA IIIV , myocardial infarction , know cardiovascular disease include hypertension &gt; 160/95mmHg ( measure training visit timepoints Day 1 ) , stroke TIA 7 Neurological disorder ( epilepsy ) psychiatric disorder 8 Acute relevant chronic infection ( e.g . HIV , repeat urogenital infection ) 9 Any gastrointestinal , hepatic , respiratory , endocrine immunological disorder 10 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 11 . A marked baseline prolongation QT/QTc interval ( e.g. , ECG demonstration QTc interval &gt; 450 m ) screen visit</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>